Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma

Table 1 Baseline clinicopathological parameters of enrolled patients

Parameters	No.
Age (years)
≤ 65	23
> 65	7
Gender
Male	29
Female	1
HBV infection
Yes	29
No	1
HCV infection
Yes	0
No	30
Child–Pugh score
A	28
B	2
AFP (ng/mL)
≤ 400	17
> 400	13
PIVKA (mAU/mL)
Median level	1423.50
ECOG-PS
0	29
1	1
BCLC stage
B	4
C	26

HBV: Hepatitis B virus; HCV: Hepatitis C virus; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; PIVKA: Protein induced by vitamin K absence.

Table 2 Incidence of adverse events in the patients following treatment, n (%)

AEs	Any grade No.	Grade 1 No. (%)	Grade 2 No. (%)	Grade 3 No. (%)	Grade 4 No. (%)	Grade 5 No. (%)
Palmar-plantar erythrodysesthesia	17 (56.7)	7	8	2	0	0
Rash	12 (40)	5	5	2	0	0
Diarrhea	5 (16.7)	0	2	0	1	0
Hypertension	4 (13.3)	3	1	0	0	0
Hair loss	4 (13.3)	2	2	1	0	0
Fatigue	2 (6.7)	0	1	1	0	0
Gastrointestinal hemorrhage	1 (3.33)	0	0	1	0	0

AE: Adverse events.

Table 3 Evaluation of the treatment efficacy

Tumor response	Value
CR	10% (3/30)
PR	50% (15/30)
ORR	60%
SD	33.3% (10/30)
PD	6.7% (2/30)
DCR	93.3%
Median TTP	6.3
Median DOR	6.6
Median PFS	11.8

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; PFS: Progression-free survival; ORR: Objective response rate; DCR: Disease control rate; TTP: Time to progression; DOR: Duration of response.